{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:10:51Z","timestamp":1786590651349,"version":"build-2736575974"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81300169"],"award-info":[{"award-number":["81300169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81270289"],"award-info":[{"award-number":["81270289"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Pillar Program of Sichuan Province","award":["2013SZ0082"],"award-info":[{"award-number":["2013SZ0082"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0159079","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T13:34:27Z","timestamp":1469021667000},"page":"e0159079","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway"],"prefix":"10.1371","volume":"11","author":[{"given":"Chen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangbo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiying","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,7,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.physiol.65.092101.142243","article-title":"Cardiac hypertrophy: the good, the bad, and the ugly","volume":"65","author":"N Frey","year":"2003","journal-title":"Annu Rev Physiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0140-6736(06)68074-4","article-title":"Controversies in ventricular remodelling","volume":"367","author":"LH Opie","year":"2006","journal-title":"The Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.4049\/jimmunol.180.11.7349","article-title":"Bacillus Calmette-Guerin and TLR4 Agonist Prevent Cardiovascular Hypertrophy and Fibrosis by Regulating Immune Microenvironment","volume":"180","author":"YY Liu","year":"2008","journal-title":"J Immunol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.pharmthera.2012.06.006","article-title":"Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets","volume":"135","author":"J Hou","year":"2012","journal-title":"Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.physiol.63.1.391","article-title":"Cytoplasmic Signaling Pathways That Regulate Cardiac Hypertrophy","volume":"63","author":"JD Molkentin","year":"2001","journal-title":"Annu Rev Physiol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nm.1893","article-title":"A new type of ERK1\/2 autophosphorylation causes cardiac hypertrophy","volume":"15","author":"K Lorenz","year":"2009","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1749-6632.2009.05088.x","article-title":"Extracellular signal-regulated kinase 1\/2 (ERK1\/2) signaling in cardiac hypertrophy","volume":"1188","author":"I Kehat","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"9806","DOI":"10.1073\/pnas.1301509110","article-title":"Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy","volume":"110","author":"BS Ferguson","year":"2013","journal-title":"PNAS"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/cvr\/cvs249","article-title":"beta-Adrenergic receptor stimulation causes cardiac hypertrophy via a Gbetagamma\/Erk-dependent pathway","volume":"96","author":"M Vidal","year":"2012","journal-title":"Cardiovasc Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cardiores.2005.06.020","article-title":"Endothelin-1 and isoprenaline co-stimulation causes contractile failure which is partially reversed by MEK inhibition","volume":"68","author":"F Munzel","year":"2005","journal-title":"Cardiovasc Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1582-4934.2008.00620.x","article-title":"Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1\/2 signalling pathway","volume":"13","author":"J Cai","year":"2009","journal-title":"J Cell Mol Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-8722-3-8","article-title":"From basic research to clinical development of MEK1\/2 inhibitors for cancer therapy","volume":"3","author":"C Fremin","year":"2010","journal-title":"J Hematol Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-6-27","article-title":"MEK and the inhibitors: from bench to bedside","volume":"6","author":"A Akinleye","year":"2013","journal-title":"J Hematol Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"TC Yeh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/cvr\/cvr301","article-title":"Treatment with selumetinib preserves cardiac function and improves survival in cardiomyopathy caused by mutation in the lamin A\/C gene","volume":"93","author":"A Muchir","year":"2012","journal-title":"Cardiovasc Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0008-6363(95)00133-6","article-title":"Arachidonic acid disrupts calcium dynamics in neonatal rat cardiac myocytes","volume":"30","author":"P Hoffmann","year":"1995","journal-title":"Cardiovasc Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.biocel.2009.08.002","article-title":"Cardiac hypertrophy: targeting Raf\/MEK\/ERK1\/2-signaling","volume":"41","author":"K Lorenz","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0248-4900(93)90138-5","article-title":"MAP kinase kinase: A node connecting multiple pathways","volume":"79","author":"G Mordret","year":"1993","journal-title":"Biol Cell"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1078-0432.CCR-13-1311","article-title":"Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial","volume":"20","author":"N Jain","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(13)70237-7","article-title":"Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study","volume":"14","author":"C Robert","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-12-3476","article-title":"Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E\/K-Mutated Melanoma","volume":"19","author":"F Catalanotti","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"J Farley","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","article-title":"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study","volume":"14","author":"PA Janne","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1078-0432.CCR-11-0563","article-title":"Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements","volume":"18","author":"DN Hayes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial","volume":"311","author":"RD Carvajal","year":"2014","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2012.144","article-title":"Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma","volume":"106","author":"CMM Prado","year":"2012","journal-title":"Br J Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2044-5040-3-17","article-title":"Inhibition of extracellular signal-regulated kinase 1\/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A\/C gene mutation","volume":"3","author":"A Muchir","year":"2013","journal-title":"Skeletal Muscle"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.18632\/aging.100503","article-title":"Modeling of lamin A\/C mutation premature cardiac aging using patient\u2010specific induced pluripotent stem cells","volume":"4","author":"CW Siu","year":"2012","journal-title":"Aging"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.HYP.0000121223.44837.de","article-title":"Left Ventricular Concentric Geometry During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive Patients","volume":"43","author":"ML Muiesan","year":"2004","journal-title":"Hypertension"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jcp.21197","article-title":"Activation or inactivation of cardiac Akt\/mTOR signaling diverges physiological from pathological hypertrophy","volume":"214","author":"OJ Kemi","year":"2008","journal-title":"J Cell Physiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/sj.onc.1210392","article-title":"Differential regulation and properties of MAPKs","volume":"26","author":"M Raman","year":"2007","journal-title":"Oncogene"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.1073\/pnas.1221999110","article-title":"Interference with ERKThr188 phosphorylation impairs pathological but not physiological cardiac hypertrophy","volume":"110","author":"C Ruppert","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"14074","DOI":"10.1073\/pnas.0610906104","article-title":"Genetic inhibition of cardiac ERK1\/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo","volume":"104","author":"NH Purcell","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.CIR.0000138190.50127.6A","article-title":"Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload","volume":"110","author":"IS Harris","year":"2004","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCRESAHA.110.231514","article-title":"Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth","volume":"108","author":"I Kehat","year":"2011","journal-title":"Circ Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0159079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T09:24:12Z","timestamp":1540027452000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0159079"}},"subtitle":[],"editor":[{"given":"Luis Eduardo M","family":"Quintas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,7,20]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0159079","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,20]]}}}